Hyderabad, India-based Dr. Reddy’s Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg, and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market. Dr. Reddy’s received approval by the Food and Drug Administration (FDA).
The Lunesta tablets C-IV brand and generic combined had US sales of approximately $887 million MAT for the most recent 12 months ending in January 2014, according to IMS Health National Sales Perspectives.
Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.
